SCGN and Alzheimer disease: Post mortem studies found that colocalization of secretagogin and hyperphosphorylated tau was negligable in brains from patients with AD of Braak stage III or higher and that the number of secretagogin-positive cells was not significantly changed in brains with different tau burden (Attems et al., 2008).